COGRX Logo.jpg
Cognition Therapeutics Initiates NIA-Funded SPARC Study of Elayta™ to Assess Changes in Synaptic Density and Cognitive Performance in Alzheimer's Disease
June 18, 2018 08:03 ET | Cognition Therapeutics, Inc.
Pittsburgh, June 18, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurocognitive disorders, today...
2020-0227 Cognition Logo for GNW.png
Cognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting on November 2nd and 4th
October 30, 2017 08:12 ET | Cognition Therapeutics, Inc.
PITTSBURGH, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
2020-0227 Cognition Logo for GNW.png
Cognition Therapeutics CEO Kenneth I. Moch to Present at Ladenburg Thalmann 2017 Healthcare Conference
September 20, 2017 08:00 ET | Cognition Therapeutics, Inc.
PITTSBURGH, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...